- Radspherin® continues to show a favorable safety and tolerability profile
- No serious adverse event in the trial was assessed as possibly related to Radspherin®
- Independent Data Monitoring Committee recommended continuing the trial without modification
- Interim efficacy readout on track for April 2027
Oslo, Norway, 17 November 2026: Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that no serious adverse event was related to Radspherin® in the interim safety analysis of its ongoing randomized Phase 2 trial (RAD-18-003, NCT06504147) in patients with peritoneal metastases from advanced ovarian cancer. These are the first randomized, controlled safety data for Radspherin®.